Evermine 50 EES- KLES Study

A study to evaluate safety and performance of the Evermine 50 Everolimus Eluting Coronary Stent System in the treatment of patients with de novo coronary artery lesions

Study Design

- A retrospective, single-center, real-world study
- A total of 171 subjects

CTRI No.	CTRI/2017/09/009939
Study Objective	To evaluate safety and performance of the Evermine 50 everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions
Primary Outcomes	 Major Adverse Cardiac Events Clinically Driven Target Lesion Revascularization Stent Thrombosis
Secondary Outcomes	 Ischemic Driven Target Lesion Revascularization Ischemic Driven Target Vessel Revascularization Procedural success Device success
Clinical Sites	Single Center
Sample Size	A total of 171 subjects
Follow-Up	Follow-up visits at 1 month, 6 months and 12 months
Study Duration	Study started in April 2016 Study completed in October 2017

References:

1) Clinical Trial Registry- India (CTRI)

http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=20257&EncHid=&userName=Meril

- 2) Patted SV. Biodegradable polymer Evermine 50™ everolimus eluting coronary stent system with ultrathin (50 μm) strut. Integrative Clinical Medicine. 2018, Volume 2(3): 1-2.
- 3) Patted SV. Real World Experience with Ultra-low Strut Thickness Everolimus Eluting DES Evermine 50. INDIA LIVE 2017.
- 4) Patted SV. Clinical outcomes of ultrathin strut biodegradable polymer coated everolimuseluting coronary stent system in treatment of patient with de novo coronary artery lesions. Euro PCR 2018.
- 5) Presented by Ashok Thakkar. Outcomes of Ultrathin Strut Biodegradable Polymer Coated Everolimus-Eluting Coronary Stent in Patients with Coronary Artery Disease. At TCT-2018.